Elevance Health (NYSE:ELV) Price Target Lowered to $395.00 at Jefferies Financial Group

Elevance Health (NYSE:ELV) had its target price reduced by investment analysts at Jefferies Financial Group from $401.00 to $395.00 in a research note issued to investors on Friday,MarketScreener reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s target price suggests a potential upside of 14.29% from the stock’s previous close.

ELV has been the subject of a number of other research reports. Mizuho set a $413.00 price objective on shares of Elevance Health in a research report on Friday, January 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $332.00 price target on shares of Elevance Health in a report on Thursday. Wall Street Zen raised Elevance Health from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group set a $400.00 price target on shares of Elevance Health in a research report on Thursday. Finally, The Goldman Sachs Group initiated coverage on shares of Elevance Health in a research report on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 price objective on the stock. Thirteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and an average price target of $396.90.

Elevance Health Price Performance

Elevance Health stock opened at $345.62 on Friday. The firm’s fifty day moving average is $351.69 and its 200 day moving average is $329.03. The company has a quick ratio of 1.56, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The company has a market cap of $76.81 billion, a price-to-earnings ratio of 13.76, a PEG ratio of 1.88 and a beta of 0.51. Elevance Health has a 52-week low of $273.71 and a 52-week high of $458.75.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. During the same quarter in the previous year, the business earned $3.84 EPS. Elevance Health’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts forecast that Elevance Health will post 33.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Elevance Health

A number of institutional investors and hedge funds have recently bought and sold shares of ELV. Vanguard Group Inc. grew its stake in shares of Elevance Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after purchasing an additional 141,747 shares during the period. Wellington Management Group LLP increased its holdings in shares of Elevance Health by 4.8% in the third quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock valued at $2,139,473,000 after purchasing an additional 303,099 shares in the last quarter. Sanders Capital LLC raised its position in shares of Elevance Health by 24.7% during the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after acquiring an additional 1,152,440 shares during the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after purchasing an additional 901,626 shares during the last quarter. Finally, First Eagle Investment Management LLC grew its holdings in Elevance Health by 25.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after acquiring an additional 798,457 shares during the period. Institutional investors own 89.24% of the company’s stock.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.